Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dade Behring, Inc.
Abbott gets sublicense for use of PlGF in diagnosis of cardiovascular diseases
February 5th, 2006
Dade Behring, Inc., (DADE), a clinical diagnostics company, has granted a nonexclusive sublicense to Abbott for the worldwide rights for the use of the emerging cardiac marker placental growth factor (PlGF), for further development of tests for the diagnosis and prognosis of cardiovascular diseases. Studies show levels of PlGF may be useful in the prognosis of acute coronary syndrome (ACS), a heart condition that impacts millions of people worldwide. By offering rights to this emerging cardiac marker to Abbott, its availability can be expanded to a larger spectrum of global healthcare providers. No additional terms of the agreement were disclosed. ...
Source: Women's Health Law Weekly (2006-02-05)
|
